Accelerate Diagnostics Inc. (AXDX)
NASDAQ (CM) NASDAQ (CM) Primary 
XMEX Summary
Accelerate Diagnostics, Inc. (AXDX) Q3 2024 Earnings Call Transcript
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the Accelerate Diagnostics Inc. Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.92 per share a year ago.
Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System
AXDX's Arc system gains FDA clearance, automating blood culture prep for faster microbial ID, improved sepsis outcomes and reduced hospital costs.
Accelerate Diagnostics Inc. Profile
| - Industry | - Sector | Jack Phillips CEO | NASDAQ (CM) Exchange | 00430H102 CUSIP |
| US Country | 107 Employees | - Last Dividend | 12 Jul 2023 Last Split | 18 Nov 1996 IPO Date |
Overview
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing innovative solutions for the diagnosis of serious infections. Operating in the United States, Europe, and the Middle East, the company focuses on addressing the critical need for speedy identification and antibiotic susceptibility testing of infectious pathogens. Originally known as Accelr8 Technology Corporation, the company underwent a rebranding to Accelerate Diagnostics, Inc. in December 2012. With its incorporation in 1982 and headquarters in Tucson, Arizona, Accelerate Diagnostics, Inc. stands as a key player in advancing the field of infectious disease diagnosis through its cutting-edge technologies.
Products and Services
- Accelerate Pheno system
- Accelerate PhenoTest BC kit
An advanced in vitro diagnostic platform designed to facilitate the rapid identification and antibiotic susceptibility testing of pathogens responsible for serious or healthcare-associated infections, including both gram-positive and gram-negative organisms. This system is pivotal in enabling healthcare providers to make informed treatment decisions swiftly, primarily in cases where time is of the essence to prevent potentially fatal outcomes.
A comprehensive test kit specifically developed for the Accelerate Pheno system. It is designed to provide rapid identification and antibiotic susceptibility testing results for patients suspected of having bacteremia or fungemia. These conditions are known for their high morbidity and mortality risk, underscoring the critical importance of the Accelerate PhenoTest BC kit in the timely management and treatment of affected patients.
Contact Information
